Excellent website Mnholden. Thank you for this. From the website:
Total 6,950 Plans
Afrezza vs. Toujeo
Preferred 4% vs 33%
Covered 22% vs 18%
Restricted 42% vs 27%
Not Covered 32% vs. 22%
Considering that Toujeo is just replacing Lantus in all of the plans, this is not too bad of a performance for Afreeza. A note for everyone. Some plans are small and not worth pursuing. Even the good drugs are not entirely covered by every plan. The large ones are the key. Most new drugs, specially if first in its class are placed in 'restricted' because the plans want to make sure the standard of care is not immediately replaced due to reimbursement.
Tier 1 is usually for generic drugs when there is generic. Insulin has generic versions. So Tier 1 will not be possible. In any case, Tier 1 will only drive selling price down. Tier 2 is fine. Nearly all blockbuster drugs are in Tier 2.
Go to the Piper Jaffrey home page. You will see a section on the left for disclosure of company positions. The site will give you a search and type in MNKD. You will see all their ratings since 2013. On March 3/31/2014 they rated MNKD UW: $1.50 (underweight which is their equivalent for "Sell". Shortly thereafter the pps went to over $9.00 (you can see from Piper's chart).
Want to follow Piper's investment advise?
Are the five primary care specialist surveyed in India or Philippines? Seems like they like hiring from those places.
Rate at Charles Schwab is 16.7%. I got the same email. Like you, I have not received it for a while until now.
Jstockton to complete the story even more. SNY sold its share of Exubera when it became clear that Afreeza was superior. They sold Exubera to make a bid for AFreeza. Then also purchased the Exubera plant in Germany from Pfizer in anticipation of acquiring Afreeza. Check it out.
jstockton, the complete story. SNY sold its share of Exubera to Pfizer after MNKD cleared the clinical trials and started making a bid for Afreeza. Check the history books.
and may I add, upon Olivier Brandicourt's departure from Bayer to be SNY's CEO, Bayer sold its entire diabetes business. They were hoping to land Afreeza but having lost to SNY and losing their CEO to SNY, they just threw in the towel for diabetes entirely.
mmholdem, might I add, Olivier Brandicourt, the former Pfizer executive that brought in Exubera left Pfizer in frustration and became Bayer's CEO and now SNY CEO. You may not know it but Bayer was one of the bidders for the partnership with MNKD - just know it from being in the industry.
Look at MNKD's inancial statement - as of last quarter they already sold $12M to SNY. But they are reporting everything under "deferred liability" instead of sales. Products don't have to be 'prescribed' to be sold. They sell to pharmacies, not to patients. So even if it is sitting in inventory, it is sales. So your 'sales' based on prescription is what the pharmacies sell, not what MNKD sold.
657 posts | Last Activity: 8 minutes ago
Member since: Jul 20, 2015
Why would someone post 657 messages in 45 days, about 17 posts everyday on one stock?
Sorry I disagree. Ive seen this many times. They've run out of shares to short so they are creating by buying options. Mark this post. Short volume will be up again.
fragslap 336 posts | Last Activity: 1 minute 59 seconds ago Member since: Jul 21, 2015
Wow 336 posts in one month! That is an average of 110 posts a day. I hope you get paid by the post. Good luck. Hope you are making a good living.
And it is probably around 130M now with even more shorting this past few days. So do the shorts win since they are holding even more shares now? Ooops. Sorry, if you can't cover, you can't win.
Yes, I heard SNY was contacting you for a clinical trial for a brain tumor drug they are developing. Apparently the FDA approved testing on short bashers on the YMB in lieu of rats.
Don't waste your brain cells trying to make sense of basher logic. We knew when the FDA approved Afrezza that they would have to come up with all sorts of negative slant. Their strategy is to confuse everybody and create chaos. They sometimes look effective simply because they are not bound by any moral or ethical obligations. They've been wrong all along and they will be wrong all the way to oblivion. At the very minimum, there is no need to bash a stock if you don't like it. The drug works and they have no decency to want to see it help anyone.
The data was wrong and completely misleading. They were probably looking at $dollar amounts instead of units. Conceivable the $amounts of Exubera was higher simply because Exubera was too expensive.